COVID-19 Updates
Date: April 18, 2022
Issue #:
1648Summary:
The FDA has expanded the Emergency Use Authorizations
(EUAs) for the mRNA COVID-19 vaccines
manufactured by Pfizer-BioNTech(Comirnaty) and
Moderna(Spikevax) to allow for their use as a second
booster dose ≥4 months after a first booster dose in
adults ≥50 years old and in persons aged ≥12 years
(Pfizer) or ≥18 years (Moderna) who have undergone
solid organ transplantation or have a condition that
compromises the immune system to a similar extent.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: bebtelovimab Comirnaty COVID-19 Lagevrio molnupiravir nirmatrelvir Paxlovid remdesivir Ritonavir sotrovimab Spikevax vaccines Veklury Source Type: research
More News: Covid Vaccine | COVID-19 | Drugs & Pharmacology | Emergency Medicine | Norvir | Pfizer | Transplants | Vaccines